r-related hypercalcemia that is resistant to hydration. The Company
has developed G4544, an oral formulation of the active ingredient in
Ganite, that has recently entered clinical trials as a potential treatment
for diseases associated with accelerated bone loss. Ganite(R) and
Genasense(R) are available on a "named-patient" basis in countries outside
the United States. For more information about Genta, please visit our
website at:
http://www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with respect
to business conducted by Genta Incorporated. By their nature,
forward-looking statements and forecasts involve risks and uncertainties
because they relate to events and depend on circumstances that will occur
in the future. Forward- looking statements include, without limitation,
statements about:
-- the Company's ability to obtain necessary regulatory approval for
Genasense(R) from the U.S. Food and Drug Administration ("FDA") or
European Medicines Agency ("EMEA");
-- the safety and efficacy of the Company's products or product
candidates;
-- the Company's assessment of its clinical trials;
-- the commencement and completion of clinical trials;
-- the Company's ability to develop, manufacture, license and sell its
products or product candidates;
-- the Company's ability to enter into and successfully execute license
and collaborative agreements, if any;
-- the adequacy of the Company's capital resources and cash flow
projections, and the Company's ability to obtain sufficient financing
to maintain the Company's planned operations;
-- the adequacy of the Company's patents and proprietary rights;
-- the impact of litigation that has been brought against the Company
and its officers and directors and any propose
'/>"/>
SOURCE Genta Incorporated Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference2.
Syngenta Licenses Chromatin Gene Stacking Technology3.
Genta Completes Appeal of FDA Decision for Genasense(R) in CLL4.
Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market5.
Syngenta and The Royal Society of Chemistry Launch African Science Initiative6.
Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference7.
Genta Receives NASDAQ Non-Compliance Notice8.
Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis9.
Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market10.
Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy11.
Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children